- Home
- NRIX vs VMEO Comparison
NRIX vs VMEO Comparison
Compare NRIX & VMEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- VMEO
- Stock Information
- Founded
- NRIX 2009
- VMEO 2004
- Country
- NRIX United States
- VMEO United States
- Employees
- NRIX N/A
- VMEO N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- VMEO Computer Software: Prepackaged Software
- Sector
- NRIX Health Care
- VMEO Technology
- Exchange
- NRIX Nasdaq
- VMEO Nasdaq
- Market Cap
- NRIX 750.4M
- VMEO 652.9M
- IPO Year
- NRIX 2020
- VMEO N/A
- Fundamental
- Price
- NRIX $12.00
- VMEO $7.81
- Analyst Decision
- NRIX Strong Buy
- VMEO Hold
- Analyst Count
- NRIX 14
- VMEO 4
- Target Price
- NRIX $26.64
- VMEO $6.81
- AVG Volume (30 Days)
- NRIX 1.7M
- VMEO 1.6M
- Earning Date
- NRIX 10-09-2025
- VMEO 11-04-2025
- Dividend Yield
- NRIX N/A
- VMEO N/A
- EPS Growth
- NRIX N/A
- VMEO N/A
- EPS
- NRIX N/A
- VMEO 0.08
- Revenue
- NRIX $83,687,000.00
- VMEO $415,404,000.00
- Revenue This Year
- NRIX $58.48
- VMEO $2.98
- Revenue Next Year
- NRIX N/A
- VMEO $5.12
- P/E Ratio
- NRIX N/A
- VMEO $101.41
- Revenue Growth
- NRIX 48.32
- VMEO N/A
- 52 Week Low
- NRIX $8.18
- VMEO $3.64
- 52 Week High
- NRIX $29.56
- VMEO $7.90
- Technical
- Relative Strength Index (RSI)
- NRIX 66.65
- VMEO 84.79
- Support Level
- NRIX $10.28
- VMEO $7.78
- Resistance Level
- NRIX $11.70
- VMEO $7.81
- Average True Range (ATR)
- NRIX 0.79
- VMEO 0.02
- MACD
- NRIX 0.24
- VMEO -0.10
- Stochastic Oscillator
- NRIX 98.06
- VMEO 87.50
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.